Tradestie Institutional Equity Comparison Engine

PBE vs IDNA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

PBE Overall Edge

PBE Captures Institutional Edge (1โ€“1 Pillars ยท 2โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Invesco Biotechnology & Genome ETF (PBE) driven by superior Options & Structure while IDNA counters with relative strength in Momentum & Technical. Fundamentally, PBE trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus IDNA at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, PBE sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against IDNA sits in UNCLASSIFIED (20th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
PBE N/M vs IDNA N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin N/A vs N/A ยท YoY N/A vs N/A
Momentum & Technical Winner IDNA
1Y +23.4% vs +52.0% ยท 52W Pos 70% vs 74%
Options & Structure Winner PBE
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (20th %ile IV)
PBE NYSE Arca
Invesco Biotechnology & Genome ETF
Institutional Equity
$95.82
-2.1% 1D
Market Cap N/A
1M Return -0.27%
1Y Return +23.42%
Forward P/E N/M
Unified AI Score
48.8 / 100 HOLD
Tech 40.0 Fund 44.0 Flow 50.0 Mom 41.1
IDNA NYSE Arca
iShares Genomics Immunology and Healthcare ETF
Institutional Equity
$39.25
-2.12% 1D
Market Cap N/A
1M Return -3.18%
1Y Return +51.96%
Forward P/E N/M
Unified AI Score
41.7 / 100 SELL
Tech 28.0 Fund 33.0 Flow 50.0 Mom 21.8

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: PBE +23.42% IDNA +51.96% Spread: +28.54 pp (IDNA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
PBE TTM Op. Margin: N/A IDNA TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PBE vs IDNA. Trailing 12-month operating profitability (PBE N/A vs IDNA N/A) and valuation multiples (PBE N/M vs IDNA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: PBE (2) vs IDNA (1)
Institutional Metric PBE IDNA Criterion Row Winner
Market Capitalization Scale N/A N/A Larger Scale Tie
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth N/A N/A Higher Growth Tie
Operating Margin (TTM) Profitability N/A N/A Higher Margin Tie
Net Profit Margin Profitability N/A N/A Higher Margin Tie
Return on Equity (ROE) Capital Efficiency N/A N/A Higher ROE Tie
52-Week Range Position Momentum 70% ($76โ€“$105) 74% ($25โ€“$44) Stronger Trend IDNA
Beta / 30D Volatility Risk Regime 0.74ฮฒ ยท 28% Vol 1.17ฮฒ ยท 44% Vol Lower Realized Risk PBE
Unified Institutional Score Composite Signal 48.8 / 100 (HOLD) 41.7 / 100 (SELL) Higher Composite PBE

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full PBE vs IDNA Buy Guide
PBE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live PBE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IDNA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 20th %ile
IV Regime Compressed (<25th %ile)
Live IDNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither PBE nor IDNA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.